Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2003-08-07
2008-12-23
Seaman, D. Margaret (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C514S456000
Reexamination Certificate
active
07468445
ABSTRACT:
The present invention provides a method of preventing or treating one or more of the following medical conditions, or treating symptoms of one or more of the following medical conditions: amebic infections, giardiasis, estrogen deficient states, osteoporosis, cardiovascular heart disease, high cholesterol levels, hyperlipidemia, cancer by administering to a subject having, or predisposed to, one or more of the conditions, a therapeutically effective amount of a compound of the present invention and a pharmaceutically acceptable carrier.
REFERENCES:
patent: 6326366 (2001-12-01), Potter et al.
patent: 6391309 (2002-05-01), Empie et al.
patent: 6541613 (2003-04-01), Hendler et al.
patent: 6592910 (2003-07-01), Banz et al.
patent: 6593310 (2003-07-01), Cullis-Hill
patent: 6599536 (2003-07-01), Kelly et al.
patent: 0031885 (1980-11-01), None
patent: 0267155 (1987-10-01), None
patent: 0267155 (1987-10-01), None
patent: WO91/15483 (1991-10-01), None
patent: WO93/23069 (1993-11-01), None
patent: WO94/23716 (1994-10-01), None
patent: WO95/03293 (1995-02-01), None
patent: WO96/39832 (1996-12-01), None
patent: WO99/48496 (1999-09-01), None
patent: WO99/49862 (1999-10-01), None
patent: WO00/49009 (2000-08-01), None
patent: WO00/62765 (2000-10-01), None
patent: WO00/62774 (2000-10-01), None
patent: WO01/17986 (2001-03-01), None
patent: WO03/055860 (2003-07-01), None
Shao et al. STN Accession No. 1981:174809; Document No. 94:174809; Yaoxue Xuebao (1980), 15(9), 538-47.
Abdullaev; Antitrichomonas activity of different groups of substances isolated from the flora of Central Asia; Farmakol. Prir. Veschestv; 1978; pp. 103-107.
Adam, R. D. Biology ofGiardia lamblia. Clinical Microbiology Reviews 2001, 14, 447-475.
Aghoramurthy, et al.; Chemical Abstract; Columbus, OH, US; J. Indian Chem. Soc; vol. 38; 1961; pp. 914-918.
Anand, et al.; Chemical Abstract; Columbus, OH, US; J. Sci. Ind. Research; vol. 15B, 1956; p. 263.
Angarano, et. al.; Giardiasis in HIV: a possible role in patients with severe immune deficiency. European Journal of Epidemiology 1997, 13, 485-487.
Arjmandi, B. H. The role of phytoestrogens in the prevention and treatment of osteoporosis in ovarian hormone deficiency. Journal of the American College of Nutrition 2001, 20, 398S-402S.
Barat, L. M.; Bloland, P. B. Drug resistance among malaria and other parasites. Infectious Disease Clinics of North America 1997, 11, 969-987.
Belmar, et al.; Synthesis of new mesogenic compounds having the isoflavone core group; Liquid Crystals; 1999; vol. 26(1); pp. 75-81.
Brandi, M. L. Phytoestrogens and menopause. Environmental Toxicology and Pharmacology 1999, 7, 213-216.
Brandi, M. L. Natural and synthetic isoflavones in the prevention and treatment of chronic diseases. Calcified Tissue International 1997, 61, S5-S8.
Calzada, F.; Meckes, M.; Cedillo-Rivera, R. Antiamoebic and antigiardial activity of plant flavonoids. Planta Medica 1999, 65, 78-80.
Calzada, et al; Geranins A and B, New Antiprotozoal A-Type Proanthocyanidins fromGeranium niveum. Journal of Natural Products 1999, 62, 705-709.
Chakravarti, et al.; Chemical Abstracts; Columbus, OH, US; Sci. Cult; vol. 28; 1962; pp. 242-243.
Chang, et al.; Excretion of radioactive daidzein and dquol as monosulfates and disulfates in the urine of the laying hen; CA J. Biochem; 1975; vol. 53(2); pp. 2230-230.
Chudgar, et al.; Studies in isoflavones. I. Bromination, iodination, and nitration of 7-hydroxyisoflavone. J. Inst. Chem. (India) 1967, 39, 203-208.
Della Valle, F.; Romeo, A. 2-Haloresorcinols. Eur. Pat. Appl.; (Fidia S.p.A., Italy). Ep, 1985, 31 pp.
ElSohly, et al.; Antigiardial isoflavones fromMachaerium aristulatum. Planta Medica (1999), 65(5), 490.
Farkas, et al.; Chemical Abstract; Columbus, OH; Chem. Ber; vol. 91; 1958; pp. 2858-2861.
Gennari, C. Calcitonin, bone-active isoflavones and vitamin D metabolites. Osteoporosis International 1999, 9, 81-90.
Gillin, et al.; Cell biology of the primitive eukaryoteGiardia lamblia. Annual Review of Microbiology 1996, 50, 679-705.
Goldwyn, et al.; Promotion of health by soy isoflavones: efficacy, benefit and safety concerns. Drug Metabolism and Drug Interactions 2000, 17, 261-289.
Harborne, et al.; Chemical Abstracts, Columbus, OH; J. Org. Chem; vol. 28; 1963; pp. 881-882.
Jain, et al.; Flavonoids fromEschscholzia californica; Phytochemistry; 1996; vol. 41(2); pp. 661-662.
Joshi, et al.; Studies in the synthesis of furochromones. Part VIII Synthesis of furoisoflavones; IN J. Chem. Sec B: Org Chem Incl Med Chem.; 1988; vol. 27B(9); pp. 806-810.
Kalra, et al; Synthesis of 2-hydroxyisoflavones; Indian J. Chem; vol. 5(7); 1967; pp. 287-290.
Keister, D. B. Axenic culture ofGiardia lambliain TYI-S-33 medium supplemented with bile. Transactions of the Royal Society of Tropical Medicine and Hygiene 1983, 77, 487-488.
Khan, et al.; Antigiardial Activity of Isoflavones fromDalbergia frutescensBark. Journal of Natural Products 2000, 63, 1414-1416.
Khan, et al.; Antigiardial Activity of Isoflavones fromDalbergia frutescensBark. Journal of Natural Products (2000), 63(10), 1414-1416.
Khilya, et al.; Reaction of isoflavones and their 4-thioxo analogs with hydroxylamine; Ukrainskii Khimicheskii Zhurnal (Russian Edition); 1990; vol. 56(3); pp. 280-286.
Khilya, et al.; Synthetic analogs of natural isoflavones; Ukrainskii Khimicheskii Zhurnal (Russian Edition); 1984; vol. 50(12); pp. 1301-1306.
Kiehlmann, E.; Lauener, R. W. Bromophloroglucinols and their methyl ethers. Can. J. Chem. 1989, 67, 335-344.
Kitagawa, et al.; Aryloxyacetic acid diuretics with uricosuric activity. II. Substituted ‘’(4-oxo-4H-1-benzopyran-7-yl)oxylacetic acids and the related compounds; Chem & Pharm Bulletin; 1991; vol. 39(10); pp. 2681-2690.
Lal, G. S.; Pez, G. P.; Syvret, R. G. Electrophilic NF Fluorinating Agents. Chemical Reviews (Washington, D. C.) 1996, 96, 1737-1755.
Lehmann, et al; Studies on biological activity of isoflavones in cultivated V79 cells; Lebensmittelchemie; 1999; vol. 53(5); p. 124.
Lei, et al.; Synthesis and preliminary studies on bioactivities of 7-hydroxy-4′-methylisoflavone; Zhongguo Yaowu Huaxue Zazhi; 2001; vol. 11(5); pp. 270-273.
Levy, et al.; Surveillance for waterborne-disease outbreaks—United States, 1995-1996. Morbidity and Mortality Weekly Report. CDC Surveillance Summaries 1998, 47, 1-34.
Liao, et al.; Theoretical study of nuclear magnetic resonance spectra of isoflavone derivatives with m-substituents on B ring; Sichuan Shifan Daxue Xuebao, Ziran Kexueban; 2002; vol. 25(6); pp. 632-636.
Liu, et al.; 1H NMR studies on synthetic isoflavones with p-substituents on B ring; Gaodeng Xuexiao Huaxue Xuebao; 2000; vol. 21(1); pp. 1671-1674.
Liu, et al.; Studies on synthesis and antitumor activities of soybean isoflavones and their derivatives; Yaoxue Xuebao; 2000; vol. 35(8); pp. 583-586.
Luk 'Yanchikov, et al.; Synthesis of analogs of natural isoflavones via 2, 4-dihydroxydeoxybenzoins; Khimiya Prirodnykh Soedinenii; 1985; vol. 6; pp. 781-784.
Marshall, et al.; Waterborne protozoan pathogens. Clinical Microbiology Reviews 1997, 10, 67-85.
Meckes, M.; Calzada, F.; Tapia-Contreras, A.; Cedillo-Rivera, R. Antiprotozoal properties ofHelianthemum glomeratum. Phytotherapy Research 1999, 13, 102-105.
Mineno, et al.; Solution-phase parallel synthesis of an isoflavone library for the discovery of novel antigiardial agents; Combinatorial Chemistry and High Throughput Screening; vol. 5(6); 2002; pp. 481-487.
Messina, M. Soyfoods and soybean phyto-estrogens (isoflavones) as possible alternatives to hormone replacement therapy (HRT). European Journal of Cancer 2000, 36, S71-S72.
Moolasart, P.Giardia lambliain AIDS patients with diarrhea. Journal of the Medical Association of Thailand 1999, 82, 654-659.
Polkowski, K.; Mazurek, A. P. Biological properties of genistein a review of in vitro and in vivo data. Acta Poloniae Pharmaceutica 2000, 57, 135-155.
Ruenitz, P. C. Drugs of osteoporosis prevention: mechanisms of bone maintenance. Curr. Med. Chem. 1995, 2, 791-802.
Sepulveda-Boza, et al.; The preparation of new isoflavones; Synthetic Comm; 2001; vol
Avery Mitchell
Telang Nakul
Walker Larry A.
Chandrakumar Nizal S
Myers, Jr. Richard S.
Seaman D. Margaret
Stites & Harbison PLLC
University of Mississippi
LandOfFree
Antigiardial agents and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antigiardial agents and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antigiardial agents and use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4030927